# Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer

> **NCT01479036** · PHASE3 · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 800 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** docetaxel and epirubicin
- **DRUG:** docetaxel and epirubicin plus endostatin

## Key facts

- **NCT ID:** NCT01479036
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-10
- **Primary completion:** 2014-12
- **Final completion:** 2015-02
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2011-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01479036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01479036, "Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01479036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*